Introduction {#sec1-1}
============

Osteoarthritis (OA) is the most prevalent joint disease with typical characteristics, such as joint-space narrowing, and subchondral sclerosis, which induces swelling, reduces moving, stiffness and pain, and brings great cost burden to the society\[[@ref1]\]. Epidemiological evidences revealed a potential link between cartilage damage and inflammatory synovium\[[@ref2]\], because inflammation exerted important effects on the occurrence and progression of OA even in the early stage\[[@ref3]\].

As a member of transforming growth factor-β (TGF-β) family, activin A performs various functions in different tissues. There are three forms of activin: activin A, activin B, and activin AB\[[@ref4]\]. Activin A is released by various types of cells early and services as a part of the circulatory cytokine cascade in response to inflammatory compounds to participate in the process of inflammation\[[@ref5]\]. Recently, El-Gendi et al. (2010) reported that serum activin A concentrations were significantly increased in OA subjects in comparison with the controls\[[@ref6]\]. In addition, activin A promoted the proliferation of fibroblast-like synoviocytes (FLS)\[[@ref7]\], resulting in the destroyed articular bone and cartilage in OA process. Therefore, we hypothesized that activin A might be a great regulator in OA development and progression.

This study was performed to explore the relationship between the concentration of activin A and the occurrence and severity of knee OA.

Materials and methods {#sec1-2}
=====================

Participants {#sec2-1}
------------

A total of 360 participants including 210 knee OA patients (case group) and 150 healthy participants (control group) were enrolled in this study. The case and control groups were in a matched age and gender distribution ([Table 1](#T1){ref-type="table"}). According to criteria specified in American College of Rheumatology, knee OA patients were diagnosed. Exclusion criteria for knee OA patients included malignant tumors, rheumatoid arthritis or inflammatory knee disease, corticosteroids medications, and systemic or autoimmune diseases. The participants in the control group were all with normal knee radiographs and would be excluded if they had arthritis history. This research received approval from the Human Ethics Review Committee of Jingzhou Central Hospital. All participants signed the consent form.

###### 

The characteristics between knee OA patients and healthy controls.

  Characteristics              Knee OA patients (n=210)   Healthy controls (n=150)   *P* value
  ---------------------------- -------------------------- -------------------------- -----------
  Age (years)                  61.10±10.24                61.79±9.13                 0.515
  Gender (male/female)         77/133                     61/89                      0.442
  Activin A in serum (pg/mL)   220.55±25.38               100.66±8.33                \<0.001
  Activin A in SF (pg/mL)      87.83±7.52                 \_\_                       \_\_

Kellgren and Lawrence (KL) were applied for evaluation for severity of knee OA. Participants with KL grade ≥2 and 0 were considered as OA diagnosis and controls, respectively.

Laboratory methods {#sec2-2}
------------------

Blood was collected from the case and control groups and put in 1.5ml Eppendorf tube containing 7.5 µl Heparin 1000 u/ml. Then blood samples were centrifuged at 14.000 rpm for 5 min at 4°C. Serum was separated and stored at -20°C for detecting the concentrations of activin A. SF was abstracted from the knees of OA patients before hyaluronic acid medication process. Commercially available enzyme-linked immunosorbent assay (ELSIA) kits (R&D company, Farmington Hills, MI, USA) were used to measure concentrations of activin A in serum and SF.

Statistical analysis {#sec2-3}
--------------------

Data were showed as a form of means ± standard deviation (SD). The chi-square tests, unpaired t-test, or Mann-Whitney U test were used to compare case and control groups. Kruskal-Wallis test was applied for comparison of activin A concentrations among different KL grading. As for correlation between activin A concentrations and KL grading, spearman correlation analysis and multinomial logistic regression analysis were applied for analyzing the data. A *P* value \<0.05 was considered to be statistically significant based on two-tailed tests.

Results {#sec1-3}
=======

Concentrations of serum activin A between case and control groups {#sec2-4}
-----------------------------------------------------------------

As shown in \[[Table 1](#T1){ref-type="table"}\], the concentration of serum activin A (220.55±25.38 pg/mL, ranged from 177.50 to 252.18 pg/mL) in the case group was relatively higher than that in the control group (100.66±8.33, ranged from 76.73 to118.30 pg/mL) (*P*\<0.001). Activin A concentration in SF was 87.83±7.52 pg/mL in knee OA patients, but there was no results obtained form the control group because they refused to take samples of SF.

Correlation of activin A concentration with KL grades {#sec2-5}
-----------------------------------------------------

Results in \[[Table 2](#T2){ref-type="table"}\] suggested that concentrations of activin A in serum and SF were the highest in knee OA patients with KL grade 4, and the lowest in KL grade 2. As evaluated by KL grading criteria, concentrations of activin A in serum and SF were found to be significantly related to the severity of disease.

###### 

The activin A concentrations in serum and SF of knee OA patients with different KL grades.

  Activin A (pg/mL)   Grade 2 (n=67)                                   Grade 3 (n=92)                                 Grade 4 (n=51)                                                                   *P* value   r
  ------------------- ------------------------------------------------ ---------------------------------------------- -------------------------------------------------------------------------------- ----------- -------
  Serum               196.00±23.46^[\#](#t2f2){ref-type="table-fn"}^   218.24±37.79[\*](#t2f1){ref-type="table-fn"}   241.97±21.35[\*](#t2f1){ref-type="table-fn"}^[\#](#t2f2){ref-type="table-fn"}^   \<0.001     0.353
  SF                  79.42±12.32^[\#](#t2f2){ref-type="table-fn"}^    87.34±10.28[\*](#t2f1){ref-type="table-fn"}    103.24±18.23[\*](#t2f1){ref-type="table-fn"}^[\#](#t2f2){ref-type="table-fn"}^   \<0.001     0.387

P\<0.01 vs KL grade 2;

P\<0.01 vs KL grade 3.

Additionally, through spearman correlation analysis, a positive correlation between both concentrations of activin A and KL grades was found in serum (r=0.353, *P*\<0.001) and SF (r=0.387, *P*\<0.001). After multinomial logistic regression analysis, concentrations of activin A in serum (*P*\<0.001) and SF (*P*\<0.001) exhibited a significant correlation with KL grades ([Table 2](#T2){ref-type="table"}).

Discussion {#sec1-4}
==========

Activin A was revealed to play an important role in occurrence and progression of OA. Previous study reported a significant higher serum activin A concentration in OA patients\[[@ref6]\]. Another study also showed that activin A concentrations were promoted in OA cartilage compared to normal cartilage\[[@ref7]\]. In this study, we also demonstrated the increase of activin A concentrations in patients with knee OA. In addition, our results revealed a close relationship between activin A concentrations and disease severity of OA. Nowadays, more and more studies have focused on the aspects of biomarkers which can be utilized to predict the disease in an early step and the prognosis of different disease. Therefore, our findings supported the idea that activin A concentrations could be a biomarker to predict risk for developing OA and evaluate severity of disease or progression of OA.

Numerous studies confirmed that activin A was involved in the pathogenesis of OA. For instance, activin A mRNA and protein were enhanced in dissection and culture of human or porcine articular cartilage, indicating a potentially anticatabolic role of activin A in articular cartilage\[[@ref8]\]. Cartilage/joint injury in mice caused the increased expression of activin A gene\[[@ref9]\]. Furthermore, as a key player in OA pathogenesis, fibroblast-like synoviocytes (FLS) could generate matrix degrading enzymes and pro-inflammatory cytokines, and erode cartilage and subchondral bone, which contributed to the development and progression of OA\[[@ref10]\]. Recombinant activin A was found to promote FLS proliferation. On the other hand, follistatin, an endogenous activin antagonist, partially suppressed FLS proliferation induced by interleukin-1β (IL-1β)\[[@ref11]\].

Inflammation is a clear mechanism of OA. It was reported that macrophages from rheumatoid arthritis (RA) joints promoted the acquisition of pro-inflammatory markers\[[@ref12]\]. However, anti-activin A-neutralizing antibody suppressed pro-inflammatory polarizing ability of macrophages, suggesting the important role of activin A in macrophage-derived cytokines production\[[@ref12]\]. IL-1, an inflammatory factor, could significantly increase the expression levels of activin A gene in chondrocytes\[[@ref13],[@ref14]\]. Furthermore, IL-1β, TGF-β, and TNF-α activated FLS to secrete activin A\[[@ref11]\]. All those findings indicated that activin A was interacted with inflammatory molecules and might exert the effects on occurrence and progression of OA pathogenesis due to the increased and amplified inflammatory response in cartilage.

In conclusion, a close correlation between activin A concentrations in serum and SF and grading of knee OA was found in this study. However, the findings were limited and prospective investigation are still needed to be carried out to determine an exact role of activin A in OA.
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